SEARCH

SEARCH BY CITATION

References

  • 1
    Wawer MJ, Gray R, Sewankarnbo D et al. Rates of HIV-1 tranmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191: 14031409.
  • 2
    Pinkerton SD. Probability of HIV transmission during acute infection in Rakai, Uganda. AIDS Behav 2008; 12: 677684.
  • 3
    Vernazza P, Hirschel B, Bernasconi E et al. HIV transmission under highly active antiretroviral therapy. Lancet 2008; 372: 18061807.
  • 4
    Vernazza PL, Gilliam B, Dyer JR et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997; 11: 12491254.
  • 5
    Kashuba AD, Nafziger A, Drusano GL, Bertino J. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43: 18171826.
  • 6
    Vernazza PL, Troiani L, Flepp M et al. Potent antiretroviral treatment of HIV infection results in suppression of the seminal shedding of HIV. AIDS 2000; 14: 117121.
  • 7
    Vernazza P, Hirschel B, Bernasconi E, Flepp M. HIV-positive individuals without additional sexually transmitted diseases (STD) and on effective anti-retroviral therapy are sexually non-infectious. Bul des médecins Suisse 2008; 89: 513.
  • 8
    Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493505.
  • 9
    Kalichman SC, DiBerto G, Eaton L. HIV viral load in blood plasma and semen: review and implications of empirical findings. Sex Transm Dis 2008; 35: 5560.
  • 10
    Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. Sex Transm Infect 2011; 87: 183190.
  • 11
    Nakimuli-Mpungu E, Bass JK, Alexandre P et al. Depression, alcohol use and adherence to antiretroviral therapy in Sub-Saharan Africa: a systematic review. AIDS Behav 2012; 16: 21012118.
  • 12
    Hendershot CS, Stoner S, Pantalone D, Simoni J. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr 2009; 52: 180202.
  • 13
    Shuper PA, Joharchi N, Irving H, Rehm J. Alcohol as a correlate of unprotected sexual behavior among people living with HIV/AIDS: review and meta-analysis. AIDS Behav 2009; 13: 10211036.
  • 14
    Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004; 292: 224236.
  • 15
    Eaton LA, Kalichman S. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007; 4: 165172.
  • 16
    Gribble JN, Miller H, Cooley P, Catania J, Pollack L, Turner C. The impact of T-ACASI interviewing on reported drug use among men who have sex with men. Subst Use Misuse 2000; 35: 869890.
  • 17
    Morrison-Beedy D, Carey M, Tu X. Accuracy of audio computer-assisted self-interviewing (ACASI) and self-administered questionnaires for the assessment of sexual behavior. AIDS Behav 2006; 10: 541552.
  • 18
    Saunders JB, Aasland OG, Babor TF, DeLaFuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption II. Addictions 1993; 88: 791804.
  • 19
    Maisto SA, Carey MP, Carey KB, Gordon C, Gleason J. An empirical investigation of the factor structure of the AUDIT. Psychol Assess 2000; 12: 346353.
  • 20
    Napper L, Fisher DG, Reynolds GL, Johnson ME. HIV Risk Behavior Self-Report Reliability at Different Recall Periods. AIDS Behav 2009; 14: 152161.
  • 21
    Bangsberg DR, Hecht FM, Charlebois ED, Chesney M, Moss A. Comparing objective measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav 2001; 5: 275281.
  • 22
    Kalichman SC, Amaral CM, Cherry C et al. Monitoring Antiretroviral adherence by unannounced pill counts conducted by telephone: reliability and criterion-related validity. HIV Clin Trials 2008; 9: 298308.
  • 23
    Kalichman SC, Amaral CM, Stearns H et al. Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone. J Gen Intern Med 2007; 22: 10031006.
  • 24
    Kalichman SC, Simbayi L, Kaufman M, Cain D, Jooste S. Alcohol use and sexual risks for HIV/AIDS in sub-Saharan Africa: systematic review of empirical findings. Prev Sci 2007; 8: 141151.
  • 25
    Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS 2012; 7: 99105.
  • 26
    Quinn TC, Wawer MJ, Sewankambo N et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342: 921929.
  • 27
    Hasse B, Ledergerber B, Hirschel B, Vernazza P. Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2010; 51: 13141322.
  • 28
    Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother 2011; 45: 372379.
  • 29
    Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 2007; 4: 6572.
  • 30
    Bangsberg DR, Deeks SG. Is average adherence to HIV antiretroviral therapy enough? J Gen Intern Med 2002; 17: 812813.